A Phase 3 interventional study of Estradiol and Progesterone in Menopause, sponsored by TherapeuticsMD. Completed at 119 sites in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-06.
Sponsored by TherapeuticsMD · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.
Among the 13 studies testing estradiol in Hot Flashes, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 8 in phase 3, and was the 13th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,845 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 431 across the 13 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 10 most frequent:
TherapeuticsMD is the lead sponsor of 6 studies on the registry; none are open to participants now.
TherapeuticsMD has 1 study filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing estradiol in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
Postmenopausal subjects with an intact uterus who meet the study entry criteria will be randomized to one of five treatment arms (four active and one placebo) and followed for 12 months. During the Screening period all subjects will be provided with a diary to self-assess the frequency and severity of their vasomotor symptoms. Subjects experiencing a minimum daily frequency of ≥7 (or ≥50 per week) moderate to severe hot flushes will participate in a VMS Substudy during the first 12 weeks of treatment. The Substudy subjects will be stratified by treatment arm within the sites, and only Substudy subjects have the possibility of being randomized to placebo. Subjects who qualify for the study except for experiencing a minimum daily frequency of ≥7 (or ≥50 per week) moderate to severe hot flushes will be stratified within sites to one of the four active treatment arms and followed for 12 months, but will not participate in the VMS Substudy. (However, VMS information will be collected from all subjects during the first 12 weeks of treatment.) All Study Subjects: Postmenopausal women with an intact uterus who seek relief from hot flushes and meet all other inclusion/exclusion criteria are eligible for 12 months of study treatment.
VMS Substudy Subjects: A subset of All Study Subjects who have ≥7 per day or ≥50 per week moderate to severe hot flushes (as determined during Screening) are eligible for the 12-week VMS Substudy and for a total of 12 months of study treatment.
Clinical evaluations will be performed at the following time points:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Be a woman with an intact uterus and a Screening serum estradiol level of ≤50 pg/mL. Postmenopausal is defined herein as:
To participate in the VMS Substudy, a subject must also report ≥7 moderate to severe hot flushes per day, or ≥50 per week, at the baseline assessment during Screening (subjects whose hot flushes are less frequent may still participate as non-Substudy subjects.
Note: A minimum of 14 consecutive days of complete hot flush diary data are required during the baseline assessment at Screening, and these consecutive days must occur within the last 14 days prior to the Randomization visit (not counting the Randomization visit day itself). The most recent 7 consecutive days of data prior to randomization (Day -7 to Day -1) will be used to determine the baseline number of mild, moderate and severe hot flushes for each subject.
Be judged by the principal or sub-investigator physician as being in otherwise generally good health based on a medical evaluation performed during the Screening period prior to the initial dose of study medication. The medical evaluation findings must include:
Exclusion Criteria:
To participate in the study, a subject must NOT:
Have any of the following clinical laboratory values at Screening:
Have used estrogen alone or estrogen/progestin, SERM (selective estrogen receptor modulator), testosterone, or estrogen/testosterone for any of the following time periods:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
Drug: Estradiol · Drug: Progesterone · Drug: Placebo
Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
Drug: Estradiol · Drug: Progesterone · Drug: Placebo
Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
Drug: Estradiol · Drug: Progesterone · Drug: Placebo
Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
Drug: Estradiol · Drug: Progesterone · Drug: Placebo
Two Placebo softgel capsules taken orally once a day for twelve months.
Drug: Placebo
Also known as: 17B-estradiol, Estrace
Also known as: Prometrium
Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 4
Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 12
Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 4
Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 12
Primary Safety Endpoint: Endometrial Protection - Hyperplasia
Endometrial biopsies centrally evaluated by 2 primary pathologists using criteria from Blaustein's Pathology text. Pathologists classified bx into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus reached when 2 primary pathologist agreed on any of above categories; if primary pathologists disagreed on presence of hyperplasia, result of 3rd pathologist was utilized and final decision regarding presence of hyperplasia was based on diagnosis of majority. If all 3 reads disparate, final diagnosis based on most severe dx. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects w/biopsies following M11 meeting criteria specified plus all subjects w/biopsies positive for endometrial hyperplasia by any pathologists before M11.
Time frame: Baseline and Month 12
Endometrial Protection - Hyperplasia
Endometrial biopsies centrally evaluated by 3 primary pathologists using criteria described in Blaustein's Pathology text. Pathologists classified biopsy into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus was reached when the 2 of 3 pathologist readers agreed on any of the above categories; if all three reads were disparate, the final diagnosis was based on the most severe diagnosis. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects with biopsies following M11 meeting the criteria specified plus all subjects with biopsies positive for endometrial hyperplasia by any of the pathologists before M11.
Time frame: Baseline and Month 12
Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 1
Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 2
Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 3
Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 4
Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 5
Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 6
Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 7
Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 8
Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 9
Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 10
Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 11
Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
Time frame: Baseline and Week 12
Severity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 1
Severity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 2
Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 3
Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 4
Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 5
Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 6
Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 7
Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 8
Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 9
Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 10
Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 11
Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 12
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 1
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 2
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 3
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 4
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 5
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 6
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 7
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 8
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 9
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 10
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 11
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
Time frame: Baseline and Week 12
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 1
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 2
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 3
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 4
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 5
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 6
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 7
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 8
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 9
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 10
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 11
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
Time frame: Baseline and Week 12
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe VMS from Baseline to Week 1.
Time frame: Baseline and Week 1
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2.
Time frame: Baseline and Week 2
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3.
Time frame: Baseline and Week 3
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4.
Time frame: Baseline and Week 4
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5.
Time frame: Baseline and Week 5
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6.
Time frame: Baseline and Week 6
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7.
Time frame: Baseline and Week 7
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8.
Time frame: Baseline and Week 8
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9.
Time frame: Baseline and Week 9
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10.
Time frame: Baseline and Week 10
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11.
Time frame: Baseline and Week 11
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12.
Time frame: Baseline and Week 12
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1.
Time frame: Baseline and Week 1
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2.
Time frame: Baseline and Week 2
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3.
Time frame: Baseline and Week 3
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4.
Time frame: Baseline and Week 4
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5.
Time frame: Baseline and Week 5
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6.
Time frame: Baseline and Week 6
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7.
Time frame: Baseline and Week 7
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8.
Time frame: Baseline and Week 8
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9.
Time frame: Baseline and Week 9
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10.
Time frame: Baseline and Week 10
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11.
Time frame: Baseline and Week 11
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 - (MITT-VMS)
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12.
Time frame: Baseline and Week 12
Clinical Global Impression (CGI) - Week 4 (MITT-VMS)
The number and percentage of subjects for each possible response to the CGI at Week 4. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
Time frame: Baseline and Week 4
Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 4 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
Time frame: Baseline and Week 4
Clinical Global Impression (CGI) - Week 8 (MITT-VMS)
The number and percentage of subjects for each possible response to the CGI at Week 8. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
Time frame: Baseline and Week 8
Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 8 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
Time frame: Baseline and Week 8
Clinical Global Impression (CGI) - Week 12 (MITT-VMS)
The number and percentage of subjects for each possible response to the CGI at Week 12. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
Time frame: Baseline and Week 12
Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 12 (MITT-VMS)
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
Time frame: Baseline and Week 12
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 1 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 2 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 3 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 4 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 5 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 6 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 7 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 8 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 9 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 10 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 11 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: Cycle 12 to 13
Number of Subjects Without Bleeding for Consecutive Cycles
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
Time frame: The 13th Cycle
Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 1 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 1 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 2 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 2 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 3 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 3 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 4 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 4 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 5 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 5 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 6 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 6 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 7 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 7 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 8 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 8 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 9 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 9 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 10 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 10 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 11 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 11 to 13
Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 13
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 12 to 13 was calculated and compared between active and placebo treatments.
Time frame: Cycle 12 to 13
Number of Subjects With Cumulative Amenorrhea From the 13th Cycle
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from the 13th Cycle was calculated and compared between active and placebo treatments.
Time frame: The 13th Cycle
Subject Incidence With Spotting - Trimester 1 (Safety Pop.)
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 1
Subject Incidence With Spotting - Trimester 2 (Safety Pop.)
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 2
Subject Incidence With Spotting - Trimester 3 (Safety Pop.)
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 3
Subject Incidence With Spotting - Trimester 4 (Safety Pop.)
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 4
Number of Days With Spotting - Trimester 1 (Safety Pop.)
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 1
Number of Days With Spotting - Trimester 2 (Safety Pop.)
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 2
Number of Days With Spotting - Trimester 3 (Safety Pop.)
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 3
Number of Days With Spotting - Trimester 4 (Safety Pop.)
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 4
Subject Incidence With Bleeding - Trimester 1 (Safety Pop.)
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 1
Subject Incidence With Bleeding - Trimester 2 (Safety Pop.)
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 2
Subject Incidence With Bleeding - Trimester 3 (Safety Pop.)
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 3
Subject Incidence With Bleeding - Trimester 4 (Safety Pop.)
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 4
Number of Days With Bleeding - Trimester 1 (Safety Pop.)
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 1
Number of Days With Bleeding - Trimester 2 (Safety Pop.)
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 2
Number of Days With Bleeding - Trimester 3 (Safety Pop.)
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 3
Number of Days With Bleeding - Trimester 4 (Safety Pop.)
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
Time frame: Trimester 4
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS)
Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS)
Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS)
Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS)
Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS)
Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS)
Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS)
Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS)
Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS)
Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS)
Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS)
Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS)
Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS)
Changes in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS)
Changes in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS)
Changes in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS)
Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS)
Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS)
Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS)
Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS)
Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS)
Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS)
Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS)
Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS)
Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS)
Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS)
Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS)
Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS)
Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS)
Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS)
Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS)
Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS)
Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS)
Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS)
Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS)
Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS)
Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS)
Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS)
Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS)
Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS)
Change from Baseline (BL) to Week 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS)
Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS)
Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT)
Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT)
Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT)
Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT)
Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT)
Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT)
Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT)
Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT)
Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT)
Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT)
Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT)
Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT)
Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT)
Change in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Week 12
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT)
Change in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 6
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT)
Change in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT)
Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT)
Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT)
Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT)
Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT)
Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT)
Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT)
Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT)
Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT)
Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT)
Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT)
Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT)
Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT)
Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT)
Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT)
Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT)
Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT)
Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT)
Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT)
Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT)
Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT)
Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT)
Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT)
Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT)
Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
Time frame: Baseline and Month 12
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT)
Change from Baseline (BL) to Wk 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
Time frame: Baseline and Week 12
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT)
Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
Time frame: Baseline and Month 6
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT)
Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
Time frame: Baseline and Month 12
| Milestone | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Started | 418 | 426 | 422 | 427 | 152 |
| Completed | 284 | 305 | 312 | 281 | 93 |
| Not completed | 134 | 121 | 110 | 146 | 59 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) | -40.6 ± 30.59 | -35.1 ± 29.14 | -33.6 ± 30.64 | -38.9 ± 31.04 | -26.4 ± 27.05 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) | -55.1 ± 31.36 | -53.7 ± 31.93 | -50.2 ± 31.35 | -52.4 ± 33.90 | -40.2 ± 29.79 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS) | -0.48 ± 0.547 | -0.51 ± 0.563 | -0.40 ± 0.469 | -0.44 ± 0.514 | -0.34 ± 0.386 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS) | -1.12 ± 0.963 | -0.90 ± 0.783 | -0.76 ± 0.744 | -0.71 ± 0.806 | -0.56 ± 0.603 |
Endometrial biopsies centrally evaluated by 2 primary pathologists using criteria from Blaustein's Pathology text. Pathologists classified bx into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus reached when 2 primary pathologist agreed on any of above categories; if primary pathologists disagreed on presence of hyperplasia, result of 3rd pathologist was utilized and final decision regarding presence of hyperplasia was based on diagnosis of majority. If all 3 reads disparate, final diagnosis based on most severe dx. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects w/biopsies following M11 meeting criteria specified plus all subjects w/biopsies positive for endometrial hyperplasia by any pathologists before M11.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Primary Safety Endpoint: Endometrial Protection - Hyperplasia | 0 | 0 | 0 | 0 | 0 |
Endometrial biopsies centrally evaluated by 3 primary pathologists using criteria described in Blaustein's Pathology text. Pathologists classified biopsy into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus was reached when the 2 of 3 pathologist readers agreed on any of the above categories; if all three reads were disparate, the final diagnosis was based on the most severe diagnosis. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects with biopsies following M11 meeting the criteria specified plus all subjects with biopsies positive for endometrial hyperplasia by any of the pathologists before M11.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Endometrial Protection - Hyperplasia | 0 | 0 | 0 | 0 | 0 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS) | -12.2 ± 20.10 | -11.5 ± 20.19 | -11.0 ± 20.94 | -16.3 ± 22.28 | -13.0 ± 21.25 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS) | -26.6 ± 27.67 | -21.2 ± 24.79 | -19.0 ± 28.32 | -25.4 ± 26.63 | -21.3 ± 24.75 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS) | -34.3 ± 29.22 | -29.0 ± 26.73 | -28.1 ± 28.18 | -33.6 ± 27.76 | -25.1 ± 27.26 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS) | -40.6 ± 30.59 | -35.1 ± 29.14 | -33.6 ± 30.64 | -38.9 ± 31.04 | -26.4 ± 27.05 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS) | -45.9 ± 32.31 | -39.5 ± 28.53 | -37.1 ± 30.64 | -43.5 ± 33.31 | -31.6 ± 28.96 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS) | -49.4 ± 32.76 | -41.7 ± 29.97 | -40.1 ± 33.62 | -45.5 ± 33.14 | -32.7 ± 28.53 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS) | -51.5 ± 31.51 | -45.0 ± 30.73 | -43.8 ± 33.20 | -47.7 ± 32.18 | -33.4 ± 29.37 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS) | -52.3 ± 31.63 | -46.8 ± 30.64 | -45.4 ± 32.55 | -48.4 ± 32.82 | -36.0 ± 30.66 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS) | -52.6 ± 32.57 | -50.5 ± 31.01 | -47.4 ± 30.13 | -50.1 ± 33.92 | -36.4 ± 29.09 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS) | -53.2 ± 32.58 | -51.9 ± 32.79 | -49.0 ± 30.24 | -50.6 ± 33.36 | -37.1 ± 29.74 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS) | -53.7 ± 32.21 | -52.0 ± 31.24 | -49.4 ± 30.71 | -50.9 ± 34.33 | -36.7 ± 30.32 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS) | -55.1 ± 31.36 | -53.7 ± 31.93 | -50.2 ± 31.35 | -52.4 ± 33.90 | -40.2 ± 29.79 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS) | -0.24 ± 0.305 | -0.25 ± 0.270 | -0.23 ± 0.264 | -0.25 ± 0.327 | -0.25 ± 0.257 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS) | -0.34 ± 0.411 | -0.34 ± 0.390 | -0.27 ± 0.354 | -0.29 ± 0.314 | -0.28 ± 0.310 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS) | -0.43 ± 0.514 | -0.44 ± 0.437 | -0.32 ± 0.410 | -0.37 ± 0.424 | -0.32 ± 0.372 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS) | -0.48 ± 0.547 | -0.51 ± 0.563 | -0.40 ± 0.469 | -0.44 ± 0.514 | -0.34 ± 0.386 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS) | -0.64 ± 0.702 | -0.56 ± 0.558 | -0.44 ± 0.463 | -0.53 ± 0.610 | -0.42 ± 0.551 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS) | -0.80 ± 0.840 | -0.61 ± 0.640 | -0.54 ± 0.578 | -0.63 ± 0.763 | -0.45 ± 0.573 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS) | -0.81 ± 0.793 | -0.69 ± 0.694 | -0.63 ± 0.637 | -0.64 ± 0.764 | -0.44 ± 0.483 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS) | -0.88 ± 0.854 | -0.70 ± 0.642 | -0.65 ± 0.685 | -0.64 ± 0.745 | -0.51 ± 0.563 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS) | -0.96 ± 0.892 | -0.74 ± 0.699 | -0.73 ± 0.720 | -0.71 ± 0.772 | -0.48 ± 0.536 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS) | -1.05 ± 0.953 | -0.77 ± 0.727 | -0.78 ± 0.769 | -0.62 ± 0.739 | -0.53 ± 0.575 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS) | -1.04 ± 0.931 | -0.86 ± 0.777 | -0.78 ± 0.782 | -0.68 ± 0.767 | -0.54 ± 0.566 |
Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS) | -1.12 ± 0.963 | -0.90 ± 0.783 | -0.76 ± 0.744 | -0.71 ± 0.806 | -0.56 ± 0.603 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS) | -12.9 ± 22.12 | -12.4 ± 23.94 | -12.5 ± 24.62 | -17.7 ± 27.78 | -12.2 ± 23.76 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS) | -28.2 ± 29.45 | -22.4 ± 30.53 | -21.8 ± 31.66 | -27.8 ± 32.35 | -21.7 ± 27.45 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS) | -37.4 ± 32.33 | -30.7 ± 32.00 | -31.3 ± 30.79 | -35.6 ± 33.52 | -25.8 ± 30.41 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS) | -44.4 ± 34.53 | -37.7 ± 35.38 | -35.4 ± 34.58 | -41.5 ± 37.40 | -26.8 ± 30.52 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS) | -49.9 ± 33.86 | -42.3 ± 34.15 | -40.1 ± 32.52 | -46.8 ± 39.88 | -33.3 ± 33.49 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS) | -53.9 ± 35.34 | -44.9 ± 36.12 | -43.0 ± 34.84 | -49.4 ± 40.28 | -34.1 ± 33.32 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS) | -56.1 ± 34.55 | -48.8 ± 36.92 | -47.2 ± 34.39 | -51.5 ± 39.69 | -33.4 ± 33.71 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS) | -57.1 ± 35.91 | -50.6 ± 37.73 | -49.5 ± 34.34 | -52.4 ± 40.65 | -36.9 ± 35.53 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS) | -57.6 ± 36.43 | -54.7 ± 38.76 | -52.8 ± 33.68 | -54.5 ± 41.89 | -38.3 ± 35.04 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS) | -58.5 ± 36.86 | -56.1 ± 39.97 | -53.7 ± 34.39 | -55.7 ± 41.55 | -38.3 ± 35.52 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS) | -58.8 ± 36.58 | -57.0 ± 38.81 | -54.2 ± 34.38 | -56.1 ± 42.45 | -38.4 ± 35.85 |
Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS) | -60.3 ± 36.42 | -58.8 ± 39.59 | -54.8 ± 34.94 | -57.0 ± 41.71 | -41.7 ± 36.35 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS) | -0.06 ± 0.211 | -0.05 ± 0.206 | -0.02 ± 0.197 | -0.08 ± 0.305 | -0.07 ± 0.200 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS) | -0.16 ± 0.349 | -0.14 ± 0.342 | -0.06 ± 0.309 | -0.12 ± 0.288 | -0.11 ± 0.275 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS) | -0.25 ± 0.480 | -0.24 ± 0.402 | -0.11 ± 0.379 | -0.20 ± 0.412 | -0.15 ± 0.350 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS) | -0.31 ± 0.527 | -0.31 ± 0.540 | -0.19 ± 0.434 | -0.27 ± 0.507 | -0.17 ± 0.368 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS) | -0.46 ± 0.680 | -0.37 ± 0.546 | -0.23 ± 0.441 | -0.36 ± 0.619 | -0.24 ± 0.524 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS) | -0.62 ± 0.835 | -0.42 ± 0.627 | -0.33 ± 0.588 | -0.46 ± 0.775 | -0.27 ± 0.548 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS) | -0.65 ± 0.798 | -0.50 ± 0.687 | -0.42 ± 0.660 | -0.47 ± 0.773 | -0.27 ± 0.469 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS) | -0.70 ± 0.858 | -0.51 ± 0.633 | -0.44 ± 0.701 | -0.47 ± 0.750 | -0.33 ± 0.545 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS) | -0.78 ± 0.909 | -0.55 ± 0.708 | -0.51 ± 0.735 | -0.54 ± 0.780 | -0.31 ± 0.515 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS) | -0.87 ± 0.970 | -0.58 ± 0.731 | -0.57 ± 0.785 | -0.45 ± 0.754 | -0.35 ± 0.557 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS) | -0.86 ± 0.950 | -0.67 ± 0.788 | -0.56 ± 0.800 | -0.50 ± 0.776 | -0.36 ± 0.543 |
Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).
| scores on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS) | -0.94 ± 0.986 | -0.71 ± 0.784 | -0.54 ± 0.761 | -0.54 ± 0.824 | -0.39 ± 0.585 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe VMS from Baseline to Week 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 15 | 17 | 15 | 25 | 16 |
| >=75% Reduction | 3 | 4 | 4 | 5 | 1 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 44 | 35 | 34 | 49 | 35 |
| >=75% Reduction | 21 | 12 | 15 | 20 | 6 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 68 | 59 | 54 | 71 | 42 |
| >=75% Reduction | 38 | 24 | 21 | 29 | 15 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 82 | 70 | 74 | 81 | 41 |
| >=75% Reduction | 55 | 34 | 32 | 45 | 15 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 93 | 80 | 74 | 90 | 55 |
| >=75% Reduction | 55 | 47 | 38 | 54 | 27 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 98 | 85 | 82 | 95 | 55 |
| >=75% Reduction | 68 | 51 | 47 | 56 | 30 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 96 | 93 | 88 | 101 | 58 |
| >=75% Reduction | 71 | 63 | 56 | 58 | 32 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 102 | 98 | 90 | 100 | 60 |
| >=75% Reduction | 78 | 64 | 59 | 62 | 37 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 98 | 107 | 92 | 101 | 63 |
| >=75% Reduction | 72 | 73 | 63 | 63 | 35 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 95 | 102 | 100 | 101 | 68 |
| >=75% Reduction | 78 | 69 | 62 | 64 | 37 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 95 | 105 | 97 | 104 | 59 |
| >=75% Reduction | 79 | 74 | 65 | 68 | 34 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 98 | 104 | 94 | 99 | 67 |
| >=75% Reduction | 84 | 75 | 66 | 68 | 37 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 14 | 10 | 12 | 19 | 10 |
| >=75% Reduction | 2 | 2 | 1 | 4 | 1 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 36 | 24 | 30 | 39 | 21 |
| >=75% Reduction | 15 | 7 | 9 | 17 | 4 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 63 | 49 | 50 | 61 | 33 |
| >=75% Reduction | 33 | 14 | 15 | 22 | 6 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 80 | 62 | 65 | 73 | 35 |
| >=75% Reduction | 44 | 28 | 24 | 33 | 6 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 86 | 72 | 69 | 82 | 47 |
| >=75% Reduction | 48 | 34 | 27 | 37 | 13 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 92 | 78 | 76 | 83 | 52 |
| >=75% Reduction | 61 | 39 | 39 | 43 | 16 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 93 | 87 | 81 | 95 | 49 |
| >=75% Reduction | 63 | 46 | 44 | 47 | 16 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 98 | 85 | 90 | 93 | 54 |
| >=75% Reduction | 64 | 53 | 45 | 51 | 20 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 95 | 95 | 91 | 94 | 58 |
| >=75% Reduction | 69 | 63 | 54 | 56 | 22 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 93 | 94 | 92 | 93 | 54 |
| >=75% Reduction | 73 | 60 | 57 | 57 | 23 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 94 | 97 | 94 | 95 | 55 |
| >=75% Reduction | 71 | 64 | 52 | 62 | 26 |
Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| >=50% Reduction | 97 | 94 | 90 | 95 | 55 |
| >=75% Reduction | 73 | 64 | 50 | 58 | 32 |
The number and percentage of subjects for each possible response to the CGI at Week 4. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| (Very) Much Improved | 86 | 71 | 72 | 75 | 41 |
| Minimally Improved | 37 | 49 | 49 | 51 | 49 |
| No Change or Worse | 13 | 21 | 23 | 22 | 35 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| (Very) Much Improved | -52.5 ± 27.28 | -48.6 ± 28.87 | -46.2 ± 31.23 | -55.7 ± 25.69 | -47.0 ± 24.17 |
| Minimally Improved | -24.1 ± 23.87 | -25.9 ± 21.43 | -29.2 ± 23.26 | -28.9 ± 26.08 | -26.8 ± 17.68 |
| No Change or Worse | -6.5 ± 23.08 | -6.6 ± 16.39 | -2.7 ± 16.22 | -5.3 ± 21.97 | -5.3 ± 13.68 |
The number and percentage of subjects for each possible response to the CGI at Week 8. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| (Very) Much Improved | 101 | 103 | 98 | 93 | 62 |
| Minimally Improved | 23 | 24 | 23 | 35 | 25 |
| No Change or Worse | 6 | 12 | 13 | 13 | 30 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| (Very) Much Improved | -60.8 ± 28.49 | -55.1 ± 29.27 | -55.4 ± 29.06 | -57.8 ± 30.38 | -52.6 ± 24.62 |
| Minimally Improved | -28.7 ± 18.93 | -27.3 ± 25.22 | -27.2 ± 22.79 | -36.8 ± 24.81 | -27.0 ± 13.54 |
| No Change or Worse | -0.2 ± 28.80 | -15.2 ± 13.41 | -1.6 ± 19.93 | -7.4 ± 21.48 | -7.1 ± 21.46 |
The number and percentage of subjects for each possible response to the CGI at Week 12. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| (Very) Much Improved | 101 | 97 | 102 | 101 | 62 |
| Minimally Improved | 17 | 29 | 22 | 24 | 26 |
| No Change or Worse | 5 | 7 | 7 | 14 | 28 |
Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.
| weekly hot flushes | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| (Very) Much Improved | -58.8 ± 30.71 | -60.0 ± 28.37 | -58.2 ± 29.42 | -59.9 ± 28.01 | -56.2 ± 26.50 |
| Minimally Improved | -35.9 ± 24.78 | -34.9 ± 40.36 | -28.8 ± 21.99 | -40.6 ± 37.36 | -35.7 ± 19.55 |
| No Change or Worse | -30.7 ± 32.89 | -38.8 ± 18.99 | -8.6 ± 18.42 | -8.3 ± 31.84 | -9.2 ± 16.77 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 204 | 251 | 263 | 239 | 82 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 209 | 256 | 265 | 244 | 84 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 214 | 258 | 267 | 246 | 85 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 217 | 261 | 273 | 253 | 86 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 224 | 265 | 278 | 253 | 86 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 227 | 268 | 280 | 256 | 86 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 237 | 271 | 282 | 256 | 87 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 242 | 276 | 285 | 258 | 88 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 245 | 279 | 288 | 259 | 88 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 248 | 281 | 292 | 261 | 88 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 251 | 284 | 294 | 261 | 88 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 260 | 284 | 295 | 260 | 88 |
No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects Without Bleeding for Consecutive Cycles | 268 | 287 | 296 | 261 | 89 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 1 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 13 | 156 | 202 | 207 | 196 | 71 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 2 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 13 | 166 | 220 | 215 | 212 | 74 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 3 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 13 | 174 | 227 | 225 | 218 | 77 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 4 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 13 | 177 | 236 | 233 | 229 | 80 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 5 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 13 | 183 | 244 | 240 | 234 | 80 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 6 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 13 | 186 | 250 | 249 | 236 | 80 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 7 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 13 | 200 | 253 | 255 | 238 | 82 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 8 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 13 | 209 | 262 | 262 | 242 | 84 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 9 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 13 | 214 | 267 | 266 | 246 | 84 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 10 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 13 | 222 | 271 | 273 | 248 | 85 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 11 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 13 | 231 | 275 | 277 | 249 | 85 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 12 to 13 was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 13 | 238 | 278 | 278 | 252 | 86 |
Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from the 13th Cycle was calculated and compared between active and placebo treatments.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Subjects With Cumulative Amenorrhea From the 13th Cycle | 249 | 282 | 283 | 254 | 88 |
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Spotting - Trimester 1 (Safety Pop.) | 90 | 74 | 68 | 58 | 10 |
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Spotting - Trimester 2 (Safety Pop.) | 76 | 40 | 48 | 24 | 4 |
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Spotting - Trimester 3 (Safety Pop.) | 54 | 33 | 29 | 18 | 2 |
Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Spotting - Trimester 4 (Safety Pop.) | 47 | 21 | 27 | 18 | 4 |
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Spotting - Trimester 1 (Safety Pop.) | 3.0 ± 8.81 | 1.7 ± 6.05 | 1.3 ± 5.08 | 0.8 ± 2.29 | 0.6 ± 2.63 |
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Spotting - Trimester 2 (Safety Pop.) | 2.9 ± 8.63 | 0.9 ± 3.85 | 1.5 ± 9.16 | 0.7 ± 4.30 | 0.1 ± 0.74 |
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Spotting - Trimester 3 (Safety Pop.) | 2.5 ± 8.28 | 0.7 ± 2.55 | 0.9 ± 6.04 | 0.3 ± 1.90 | 0.0 ± 0.14 |
Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Spotting - Trimester 4 (Safety Pop.) | 1.9 ± 7.59 | 0.5 ± 3.36 | 0.8 ± 5.75 | 0.3 ± 1.17 | 0.1 ± 0.67 |
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Bleeding - Trimester 1 (Safety Pop.) | 48 | 29 | 25 | 24 | 4 |
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Bleeding - Trimester 2 (Safety Pop.) | 45 | 23 | 19 | 5 | 2 |
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Bleeding - Trimester 3 (Safety Pop.) | 25 | 21 | 16 | 7 | 1 |
Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Participants | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Subject Incidence With Bleeding - Trimester 4 (Safety Pop.) | 27 | 16 | 9 | 5 | 2 |
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Bleeding - Trimester 1 (Safety Pop.) | 1.2 ± 5.22 | 0.5 ± 2.21 | 0.5 ± 2.24 | 0.4 ± 1.79 | 0.2 ± 1.01 |
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Bleeding - Trimester 2 (Safety Pop.) | 0.9 ± 3.22 | 0.4 ± 1.85 | 0.4 ± 2.02 | 0.2 ± 1.77 | 0.1 ± 0.42 |
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Bleeding - Trimester 3 (Safety Pop.) | 0.5 ± 2.32 | 0.5 ± 2.29 | 0.2 ± 1.43 | 0.1 ± 0.67 | 0.0 ± 0.10 |
Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.
| Days | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Number of Days With Bleeding - Trimester 4 (Safety Pop.) | 0.8 ± 3.48 | 0.4 ± 2.06 | 0.2 ± 1.20 | 0.0 ± 0.26 | 0.1 ± 0.43 |
Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
| Score on a Scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS) | -3.8 ± 1.98 | -3.3 ± 2.04 | -3.3 ± 1.97 | -3.2 ± 2.13 | -2.2 ± 1.83 |
Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS) | -4.3 ± 1.94 | -4.1 ± 1.99 | -4.0 ± 2.12 | -3.5 ± 1.95 | -3.0 ± 2.26 |
Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS) | -4.0 ± 2.15 | -4.1 ± 1.77 | -4.0 ± 2.11 | -3.4 ± 1.75 | -2.8 ± 2.26 |
Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS) | -1.1 ± 1.42 | -0.9 ± 1.56 | -1.2 ± 1.69 | -1.1 ± 1.36 | -1.0 ± 1.66 |
Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS) | -1.3 ± 1.64 | -1.1 ± 1.44 | -1.1 ± 1.76 | -1.0 ± 1.57 | -1.0 ± 1.61 |
Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS) | -1.1 ± 1.51 | -1.3 ± 1.61 | -1.1 ± 1.84 | -1.0 ± 1.67 | -1.0 ± 1.61 |
Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS) | -1.1 ± 1.30 | -1.0 ± 1.32 | -1.5 ± 1.50 | -1.0 ± 1.30 | -1.0 ± 1.38 |
Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS) | -1.2 ± 1.32 | -1.1 ± 1.37 | -1.5 ± 1.61 | -1.0 ± 1.28 | -1.1 ± 1.40 |
Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS) | -1.0 ± 1.57 | -1.2 ± 1.29 | -1.4 ± 1.60 | -1.1 ± 1.44 | -0.9 ± 1.39 |
Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS) | -1.5 ± 2.03 | -1.1 ± 1.98 | -1.7 ± 2.04 | -1.4 ± 2.16 | -1.3 ± 2.22 |
Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS) | -1.3 ± 2.18 | -1.2 ± 2.03 | -1.6 ± 2.12 | -1.4 ± 2.13 | -1.3 ± 1.93 |
Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS) | -1.0 ± 2.44 | -1.5 ± 2.20 | -1.5 ± 2.26 | -1.4 ± 2.19 | -1.1 ± 2.29 |
Changes in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS) | -1.9 ± 1.20 | -1.6 ± 1.23 | -1.9 ± 1.41 | -1.7 ± 1.31 | -1.4 ± 1.36 |
Changes in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS) | -2.0 ± 1.22 | -1.8 ± 1.22 | -2.1 ± 1.50 | -1.7 ± 1.24 | -1.6 ± 1.31 |
Changes in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS) | -1.8 ± 1.45 | -2.0 ± 1.27 | -2.0 ± 1.50 | -1.7 ± 1.29 | -1.5 ± 1.50 |
Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS) | -16.7 ± 16.99 | -13.1 ± 16.22 | -18.5 ± 19.41 | -14.6 ± 18.80 | -11.5 ± 19.67 |
Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS) | -17.8 ± 17.28 | -16.0 ± 16.60 | -19.8 ± 21.18 | -16.6 ± 19.01 | -11.7 ± 19.40 |
Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS) | -14.9 ± 21.09 | -15.8 ± 17.72 | -20.6 ± 21.58 | -17.6 ± 18.81 | -10.3 ± 21.78 |
Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS) | -22.3 ± 23.72 | -17.7 ± 24.75 | -23.6 ± 25.07 | -19.3 ± 26.31 | -15.1 ± 26.65 |
Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS) | -23.5 ± 25.99 | -21.3 ± 24.42 | -26.9 ± 26.91 | -22.4 ± 26.76 | -15.4 ± 27.57 |
Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS) | -20.0 ± 28.25 | -22.3 ± 24.84 | -26.1 ± 27.21 | -26.1 ± 25.32 | -14.1 ± 28.67 |
Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS) | -0.5 ± 23.73 | -3.6 ± 25.84 | -7.1 ± 28.49 | -5.7 ± 24.65 | -5.7 ± 25.13 |
Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS) | 0.7 ± 26.29 | -5.5 ± 26.24 | -8.8 ± 24.47 | -6.1 ± 30.29 | -3.5 ± 27.08 |
Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS) | -1.1 ± 28.04 | -10.5 ± 29.43 | -6.2 ± 27.03 | -8.0 ± 26.77 | -4.5 ± 26.23 |
Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS) | -7.7 ± 26.83 | -4.3 ± 22.18 | -12.3 ± 29.62 | -7.9 ± 27.67 | -3.6 ± 25.52 |
Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS) | -9.7 ± 27.72 | -5.0 ± 27.50 | -11.0 ± 33.55 | -7.3 ± 26.96 | -2.1 ± 23.47 |
Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS) | -8.9 ± 30.41 | -7.1 ± 24.60 | -12.4 ± 34.65 | -10.8 ± 27.15 | -2.8 ± 27.60 |
Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS) | 12.8 ± 28.30 | 11.0 ± 26.57 | 17.3 ± 30.06 | 10.7 ± 28.33 | 11.3 ± 26.09 |
Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS) | 13.2 ± 28.61 | 15.2 ± 26.89 | 14.7 ± 30.12 | 15.2 ± 28.75 | 9.5 ± 27.36 |
Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS) | 10.4 ± 28.43 | 10.5 ± 31.07 | 17.6 ± 31.61 | 13.7 ± 27.70 | 10.0 ± 31.76 |
Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS) | -11.3 ± 20.70 | -9.2 ± 17.82 | -10.4 ± 22.61 | -10.8 ± 21.78 | -8.7 ± 20.62 |
Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS) | -10.1 ± 21.60 | -10.8 ± 21.46 | -12.4 ± 22.98 | -10.5 ± 23.69 | -9.6 ± 21.64 |
Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS) | -8.0 ± 22.93 | -11.1 ± 21.51 | -13.1 ± 20.03 | -13.4 ± 23.82 | -6.7 ± 25.95 |
Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS) | -15.2 ± 17.45 | -11.3 ± 17.04 | -17.7 ± 19.47 | -13.5 ± 19.65 | -9.9 ± 20.50 |
Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS) | -16.1 ± 16.64 | -14.3 ± 16.56 | -18.0 ± 20.71 | -15.7 ± 19.34 | -9.8 ± 20.37 |
Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS) | -13.3 ± 20.52 | -13.5 ± 18.04 | -18.9 ± 21.49 | -16.1 ± 20.01 | -9.1 ± 22.62 |
Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS) | -16.8 ± 17.14 | -13.1 ± 16.16 | -18.5 ± 19.34 | -14.4 ± 19.19 | -11.8 ± 19.56 |
Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS) | -17.5 ± 17.40 | -16.0 ± 16.69 | -19.8 ± 21.18 | -17.0 ± 19.02 | -11.6 ± 19.31 |
Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS) | -14.7 ± 21.13 | -15.7 ± 17.65 | -20.5 ± 21.49 | -17.4 ± 19.48 | -10.5 ± 21.71 |
Change from Baseline (BL) to Week 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
| Proportion of Net Change | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS) | 0.2 ± 0.55 | 0.2 ± 0.54 | 0.2 ± 0.45 | 0.2 ± 0.53 | 0.2 ± 0.58 |
Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
| Proportion of Net Change | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS) | 0.3 ± 0.52 | 0.2 ± 0.52 | 0.2 ± 0.57 | 0.1 ± 0.57 | 0.2 ± 0.52 |
Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
| Proportion of Net Change | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS) | 0.2 ± 0.47 | 0.3 ± 0.58 | 0.1 ± 0.57 | 0.1 ± 0.51 | 0.2 ± 0.47 |
Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT) | -3.5 ± 2.02 | -3.1 ± 2.00 | -3.1 ± 2.01 | -2.9 ± 1.94 | -2.2 ± 1.84 |
Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT) | -4.0 ± 1.95 | -3.7 ± 2.02 | -3.5 ± 2.15 | -3.3 ± 1.94 | -3.0 ± 2.26 |
Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT) | -3.8 ± 2.05 | -3.7 ± 1.89 | -3.4 ± 2.06 | -3.3 ± 1.80 | -2.8 ± 2.26 |
Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT) | -1.1 ± 1.52 | -1.0 ± 1.66 | -1.1 ± 1.58 | -1.0 ± 1.49 | -1.0 ± 1.68 |
Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT) | -1.3 ± 1.68 | -1.1 ± 1.65 | -1.1 ± 1.65 | -1.0 ± 1.55 | -1.0 ± 1.61 |
Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT) | -1.1 ± 1.65 | -1.1 ± 1.74 | -1.1 ± 1.66 | -1.0 ± 1.64 | -1.0 ± 1.61 |
Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT) | -1.1 ± 1.41 | -1.1 ± 1.44 | -1.3 ± 1.40 | -1.1 ± 1.39 | -1.0 ± 1.38 |
Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT) | -1.2 ± 1.42 | -1.1 ± 1.46 | -1.2 ± 1.46 | -1.0 ± 1.39 | -1.1 ± 1.40 |
Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT) | -1.1 ± 1.52 | -1.1 ± 1.48 | -1.2 ± 1.43 | -1.1 ± 1.50 | -0.9 ± 1.39 |
Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT) | -1.4 ± 2.06 | -1.3 ± 2.21 | -1.5 ± 2.02 | -1.5 ± 2.15 | -1.3 ± 2.21 |
Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT) | -1.4 ± 2.11 | -1.4 ± 2.12 | -1.4 ± 2.05 | -1.3 ± 2.10 | -1.3 ± 1.93 |
Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT) | -1.3 ± 2.26 | -1.4 ± 2.32 | -1.3 ± 2.10 | -1.2 ± 2.25 | -1.1 ± 2.29 |
Change in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT) | -1.8 ± 1.31 | -1.6 ± 1.38 | -1.7 ± 1.35 | -1.6 ± 1.35 | -1.4 ± 1.36 |
Change in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT) | -2.0 ± 1.32 | -1.8 ± 1.38 | -1.8 ± 1.39 | -1.7 ± 1.29 | -1.6 ± 1.31 |
Change in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT) | -1.8 ± 1.43 | -1.8 ± 1.45 | -1.7 ± 1.38 | -1.6 ± 1.38 | -1.5 ± 1.50 |
Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT) | -15.1 ± 17.64 | -13.0 ± 17.42 | -13.9 ± 17.40 | -13.3 ± 18.22 | -11.5 ± 19.60 |
Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT) | -15.6 ± 18.13 | -14.8 ± 16.10 | -14.7 ± 18.95 | -14.6 ± 18.93 | -11.7 ± 19.40 |
Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT) | -14.4 ± 18.36 | -14.5 ± 17.85 | -15.3 ± 18.78 | -15.3 ± 19.28 | -10.3 ± 21.78 |
Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT) | -21.0 ± 23.74 | -18.1 ± 24.62 | -18.7 ± 23.11 | -17.3 ± 24.88 | -14.9 ± 26.57 |
Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT) | -22.3 ± 25.24 | -20.2 ± 22.46 | -20.1 ± 25.12 | -19.4 ± 24.85 | -15.4 ± 27.57 |
Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT) | -20.2 ± 25.27 | -19.9 ± 24.90 | -19.9 ± 25.01 | -19.7 ± 24.13 | -14.1 ± 28.67 |
Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT) | -2.6 ± 25.30 | -4.7 ± 26.08 | -4.5 ± 28.93 | -3.4 ± 26.94 | -5.6 ± 25.03 |
Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT) | -2.4 ± 28.00 | -6.0 ± 25.73 | -6.8 ± 27.32 | -3.7 ± 28.98 | -3.5 ± 27.08 |
Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT) | -3.4 ± 29.62 | -7.5 ± 27.71 | -5.0 ± 28.57 | -4.5 ± 24.79 | -4.5 ± 26.23 |
Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT) | -6.0 ± 24.56 | -6.0 ± 23.67 | -7.1 ± 27.97 | -6.3 ± 27.03 | -3.4 ± 25.50 |
Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT) | -6.2 ± 28.14 | -5.9 ± 24.36 | -7.5 ± 27.19 | -5.7 ± 26.34 | -2.1 ± 23.47 |
Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT) | -6.6 ± 27.64 | -6.4 ± 23.58 | -7.9 ± 28.34 | -6.5 ± 28.07 | -2.8 ± 27.60 |
Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT) | 11.9 ± 29.12 | 9.0 ± 27.40 | 11.4 ± 27.54 | 11.9 ± 27.30 | 11.3 ± 25.98 |
Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT) | 10.5 ± 26.86 | 11.7 ± 28.11 | 11.0 ± 28.85 | 14.5 ± 27.92 | 9.5 ± 27.36 |
Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT) | 9.8 ± 27.33 | 12.0 ± 29.86 | 12.6 ± 27.71 | 14.1 ± 28.81 | 10.0 ± 31.76 |
Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT) | -9.2 ± 20.49 | -8.1 ± 18.67 | -7.6 ± 19.57 | -8.9 ± 21.09 | -8.7 ± 20.54 |
Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT) | -9.4 ± 22.40 | -8.4 ± 19.88 | -9.6 ± 20.04 | -8.7 ± 21.65 | -9.6 ± 21.64 |
Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT) | -8.5 ± 22.79 | -9.2 ± 19.17 | -9.9 ± 19.33 | -9.4 ± 23.06 | -6.7 ± 25.95 |
Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT) | -13.5 ± 17.90 | -11.4 ± 18.02 | -12.2 ± 18.29 | -12.8 ± 19.33 | -9.8 ± 20.47 |
Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT) | -14.0 ± 17.60 | -12.9 ± 16.76 | -13.2 ± 19.16 | -13.8 ± 19.77 | -9.8 ± 20.37 |
Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT) | -12.8 ± 18.19 | -13.0 ± 18.36 | -13.7 ± 19.02 | -14.0 ± 20.14 | -9.1 ± 22.62 |
Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT) | -15.1 ± 17.64 | -13.0 ± 17.38 | -13.9 ± 17.40 | -13.4 ± 18.47 | -11.8 ± 19.48 |
Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT) | -15.5 ± 18.15 | -14.6 ± 16.41 | -14.9 ± 18.95 | -14.8 ± 18.87 | -11.6 ± 19.31 |
Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.
| score on a scale | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT) | -14.3 ± 18.35 | -14.6 ± 17.95 | -15.4 ± 18.74 | -15.1 ± 19.43 | -10.5 ± 21.71 |
Change from Baseline (BL) to Wk 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
| Proportion of Net Change | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT) | 0.2 ± 0.53 | 0.1 ± 0.56 | 0.2 ± 0.49 | 0.1 ± 0.52 | 0.2 ± 0.59 |
Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
| Proportion of Net Change | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT) | 0.2 ± 0.56 | 0.2 ± 0.55 | 0.2 ± 0.53 | 0.1 ± 0.56 | 0.2 ± 0.52 |
Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.
| Proportion of Net Change | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT) | 0.1 ± 0.51 | 0.2 ± 0.56 | 0.1 ± 0.55 | 0.1 ± 0.52 | 0.2 ± 0.47 |
Collected over Adverse Event data were collected on or after the subject signed Informed Consent through fifteen days following the last dose of Investigational Product. Treatment Emergent Adverse Event data were collected on or after the first dose of IP through fifteen days following the last dose of IP.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combined Estradiol 1 mg / Progesterone 100 mg | 0/415 (0%) | 9/415 (2.2%) | 324/415 (78.1%) |
| Combined Estradiol 0.5 mg / Progesterone 100 mg | 0/424 (0%) | 15/424 (3.5%) | 277/424 (65.3%) |
| Combined Estradiol 0.5 mg / Progesterone 50 mg | 1/421 (0.2%) | 9/421 (2.1%) | 291/421 (69.1%) |
| Combined Estradiol 0.25 mg / Progesterone 50 mg | 0/424 (0%) | 11/424 (2.6%) | 232/424 (54.7%) |
| Placebo | 0/151 (0%) | 2/151 (1.3%) | 41/151 (27.2%) |
| Event | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Cholecystitis InfectiveInfections and infestations | 0/415 | 0/424 | 0/421 | 0/424 | 1/151 |
| Uterine ProlapseReproductive system and breast disorders | 0/415 | 0/424 | 0/421 | 0/424 | 1/151 |
| DiverticulitisInfections and infestations | 2/415 | 0/424 | 0/421 | 0/424 | 0/151 |
| Breast Cancer FemaleNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/415 | 1/424 | 0/421 | 0/424 | 0/151 |
| PneumoniaInfections and infestations | 0/415 | 2/424 | 0/421 | 0/424 | 0/151 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 0/415 | 0/424 | 0/421 | 2/424 | 0/151 |
| Coronary Artery DiseaseCardiac disorders | 1/415 | 0/424 | 0/421 | 0/424 | 0/151 |
| Colitis IschaemicGastrointestinal disorders | 1/415 | 0/424 | 0/421 | 0/424 | 0/151 |
| Pancreatitis AcuteGastrointestinal disorders | 1/415 | 0/424 | 0/421 | 0/424 | 0/151 |
| Gastroenteritis ViralInfections and infestations | 1/415 | 0/424 | 0/421 | 0/424 | 0/151 |
| Event | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo |
|---|---|---|---|---|---|
| Breast TendernessReproductive system and breast disorders | 45/415 | 19/424 | 25/421 | 10/424 | 1/151 |
| HeadacheNervous system disorders | 31/415 | 24/424 | 45/421 | 43/424 | 4/151 |
| NasopharyngitisInfections and infestations | 25/415 | 41/424 | 37/421 | 24/424 | 4/151 |
| Upper Respiratory Tract InfectionInfections and infestations | 22/415 | 26/424 | 34/421 | 15/424 | 6/151 |
| NauseaGastrointestinal disorders | 20/415 | 25/424 | 19/421 | 16/424 | 2/151 |
| Back PainMusculoskeletal and connective tissue disorders | 22/415 | 11/424 | 15/421 | 15/424 | 1/151 |
| Abdominal PainGastrointestinal disorders | 22/415 | 10/424 | 14/421 | 15/424 | 4/151 |
| SinusitisInfections and infestations | 20/415 | 15/424 | 13/421 | 13/424 | 3/151 |
| DizzinessNervous system disorders | 17/415 | 15/424 | 10/421 | 8/424 | 3/151 |
| Pelvic PainReproductive system and breast disorders | 17/415 | 15/424 | 10/421 | 7/424 | 0/151 |
Safety population
| Age, Categorical(Participants) | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 415 | 424 | 421 | 424 | 151 | 1835 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 54.7 ± 4.37 | 54.5 ± 4.52 | 54.9 ± 4.27 | 54.4 ± 4.04 | 54.5 ± 4.32 | 54.6 ± 4.31 |
| Sex: Female, Male(Participants) | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 415 | 424 | 421 | 424 | 151 | 1835 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Combined Estradiol 1 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 100 mg | Combined Estradiol 0.5 mg / Progesterone 50 mg | Combined Estradiol 0.25 mg / Progesterone 50 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 415 | 424 | 421 | 424 | 151 | 1835 |
Showing the first 100 of 119 sites. Choose a country and city above to see the rest.
Ran from Aug 2013 to primary completion in Oct 2016, 38 months.
Results were first posted in May 2019, 2 years 6 months after primary completion. A results delay was requested in Feb 2017.
Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Progesterone
TherapeuticsMD